ILC 2019: Interim data from two Phase 2a studies of ABI-H0731 suggest good tolerability and enhanced antiviral efficacy in combination with standard-of-care in chronic hepatitis B infection 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…
ILC 2019: Phase 1 study demonstrates that superoxide dismutase mimetic, calmangafodipir, is well tolerated and may reduce liver injury after paracetamol overdose 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) Final results from a…
ILC 2019: UK population-based study finds large numbers of young adults have nonalcoholic fatty liver disease (NAFLD) and many of these already have fibrosis 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A large…
ILC 2019: German and US studies confirm the efficacy and safety of G/P in a broad range of individuals with HCV infection and other comorbidities, showing improvements in mental and physical well-being 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
ILC 2019: Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) An interim…
ILC 2019: Orally-administered small molecule, ccc_R08, eliminates covalently closed circular DNA (cccDNA) in the liver of an HBV cccDNA mouse model: a step towards a sterilizing cure? 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…
ILC 2019: Oral faecal microbiota capsules reduce hospitalizations, improve duodenal microbial diversity, and enhance cognitive function when added to standard-of-care in individuals with cirrhosis and recurrent hepatic encephalopathy 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF…
ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) The increasing burden and…
ILC 2019: UK disease clustering study suggests that environmental exposure may play a key role in the development of some autoimmune liver diseases 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) Investigators from a…
ILC 2019: ‘Treatment as Prevention’ programme for hepatitis C in Iceland reports high levels of cure, but homelessness is found to be a barrier to success 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER)…